Upon completion of this educational activity, participants should be better able to:

• Summarize data from historical and ongoing studies examining adjuvant therapy for non-small cell lung cancer
• Review the prognostic and predictive factors for chemotherapy treatment for patients with NSCLC
• Identify the role of immunotherapies in the adjuvant setting for patients with resected stage IB-lllA NSCLC

Corey Langer, MD, FACP, Mark Socinski, MD, and Johan Vansteenkiste, MD, PhD, in a roundtable discussion, review updated clinical information regarding adjuvant therapy for treatment of resectable NSCLC with a focus on the future of immunotherapy.

Chair:                     Corey J. Langer, MD, FACP

                              University of Pennsylvania
                              Philadelphia, Pennsylvania, United States

 

Participants:            Mark A. Socinski, MD

                              University of North Carolina
                              Chapel Hill, North Carolina, United States

 
                              Johan F. Vansteenkiste, MD, PhD
                              University Hospital Gasthuisberg
                              Leuven, Belgium

There is a significant need for education regarding optimal adjuvant strategies for resectable NSCLC. The availability of novel emerging therapies is revolutionizing treatment from a ‘one size fits all’ approach to more individualized strategy. Practicing oncologists are, therefore, now faced with selecting the best treatment strategy for each patient, first-line and beyond. To do this effectively, it is essential that oncology specialists are knowledgeable about the latest results from clinical research and the implications of these data for clinical practice.

 

To optimize outcomes in patients with resectable NSCLC, there is an urgent need to address clinical knowledge gaps regarding the many recent scientific and treatment advances in this area. Because adjuvant treatment of NSCLC is multimodal and multidisciplinary, educational opportunities on this topic will reach beyond medical oncologists to the broader oncology healthcare community. Finally, due to the rapid release of data in this field, oncology specialists require a “one-stop” comprehensive educational opportunity where they can receive updates on a number of topics in the field of lung cancer. Many oncology specialists require further explanation and expert interpretation of trial data before they are able to effectively and appropriately incorporate the new information into clinical practice.

Postgraduate Institute for Medicine and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and prIME Oncology for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr Langer has disclosed that he has received consulting fees and fees from non-CME services from Genentech BioOncology and OSI Pharmaceuticals. These relationships will not impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


Dr Socinski has disclosed that he has received consulting fees from Eli Lilly and Company and Genentech BioOncology. He has also disclosed that he has performed contracted research for Celgene Corporation, Eli Lilly and Company, Genentech BioOncology, MERCK & CO., Inc., and Pfizer Inc. These relationships will not impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


Prof Vansteenkiste has disclosed that he has received consulting fees from GlaxoSmithKline. This relationship will not impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The following planners and managers, Linda Graham, RN, BSN, BA, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following planners, reviewers, and managers, Janelle Bowersox, RN, MSN, OCN (clinical), Trudy Stoddert, ELS (editorial), and Kimberly Friese, CMP (project planning), hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.